Global Gout Therapeutics Market is valued approximately at USD 2.65 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.25% over the forecast period 2024-2032. Gout, an inflammatory arthritis condition resulting from the deposition of monosodium urate crystals in joints and tissues, is characterized by severe pain, swelling, and redness, often affecting the big toe. The market for gout therapeutics is experiencing significant growth, driven by various factors including the increasing prevalence of gout worldwide, advancements in research and development, and growing awareness of early diagnosis and management of the condition.
The rising prevalence of gout is particularly notable in developed countries, attributed to aging populations, sedentary lifestyles, unhealthy diets, and the prevalence of obesity and hypertension. Continuous R&D efforts focused on developing innovative and effective gout therapeutics are further propelling market growth. Pharmaceutical companies are actively working on novel drug formulations, targeted therapies, and regenerative medicine approaches to address the unmet needs of gout patients. This includes new medications targeting specific pathways involved in gout pathogenesis and exploring biologics and gene therapies.
North America held the largest share of the global gout therapeutics market in 2021 and is projected to remain highly lucrative during the forecast period. The region's growth is driven by the high incidence of gout and associated comorbidities in the U.S., where gout is the most common inflammatory arthritis. Studies indicate that more than nine million Americans suffer from gout, with a significant portion undergoing oral urate-lowering therapies. Meanwhile, the Asia Pacific region is expected to witness rapid market growth from 2022 to 2031, spurred by increasing incidence and prevalence of gout, coupled with heightened research and development activities in gout diagnosis and treatment.
Major market players included in this report are:
Takeda Pharmaceutical Company Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
AstraZeneca plc
Horizon Therapeutics plc
Merck & Co. Inc.
Teijin Pharma Ltd.
GlaxoSmithKline, Plc.
Zydus Group
Takeda Pharmaceuticals
The detailed segments and sub-segment of the market are explained below:
By Drug Class:
NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents
Others
By Disease Condition:
Acute Gout
Chronic Gout
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
Table of Contents
Chapter 1. Global Gout Therapeutics Market Executive Summary
1.1. Global Gout Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Disease Condition
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Gout Therapeutics Market Definition and Research Assumptions